Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Equity (2016 - 2025)

Sangamo Therapeutics (SGMO) has 15 years of Return on Equity data on record, last reported at 8.43% in Q3 2025.

  • For Q3 2025, Return on Equity fell 414.0% year-over-year to 8.43%; the TTM value through Sep 2025 reached 8.43%, down 414.0%, while the annual FY2024 figure was 1.85%, 49.0% down from the prior year.
  • Return on Equity reached 8.43% in Q3 2025 per SGMO's latest filing, down from 5.17% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.26% in Q1 2021 and bottomed at 8.43% in Q3 2025.
  • Average Return on Equity over 5 years is 2.43%, with a median of 0.7% recorded in 2023.
  • Peak YoY movement for Return on Equity: tumbled -552bps in 2024, then skyrocketed 105bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.46% in 2021, then crashed by -39bps to 0.64% in 2022, then crashed by -272bps to 2.37% in 2023, then tumbled by -34bps to 3.16% in 2024, then tumbled by -166bps to 8.43% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 8.43% in Q3 2025, 5.17% in Q2 2025, and 5.74% in Q1 2025.